MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection
Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection
Taletrectinib shows efficacy and tolerability in advanced ROS1+ NSCLC previously treated with entrectinib
Giredestrant plus everolimus new option in ER+, HER2– advanced breast cancer, post-CDK4/6 inhibitors
Circulating tumour DNA a useful marker in CRC treatment efficacy, but only alongside others
Enhancing breast cancer care through AI and collaboration
NSCLC brain metastases: TTFields after SRS delays intracranial progression without affecting QoL
Proton vs photon radiotherapy shows similar patient-reported quality of life in breast cancer patients
Apalutamide and salvage radiotherapy benefits luminal B subtype prostate cancer
ctDNA testing improves detection of treatable metastases compared to standard care in colorectal cancer
ADT with PORT is a good treatment option for men with unfavourable intermediate risk or favourable high risk PC